Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: Analysis of the British NHS bridge to transplant (BTT) program

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:171

Article

Clarke, Aileen¹  Pulikottil-Jacob, Ruth¹  Connock, Martin¹  Suri, Gaurav¹  Kandala, Ngianga-Bakwin¹  Maheswaran, Hendramoorthy¹  Banner, Nicholas R.²  Sutcliffe, Paul¹ 

[1] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England

[2] Univ London Imperial Coll Sci Technol & Med, Natl Heart Lung Inst, London, England

关键词: Left ventricular assist device;    Heart failure;    Comparative cost-effectiveness;   

DOI  :  10.1016/j.ijcard.2013.12.015

来源: Elsevier

【 摘 要 】

Background: A previous cost-effectiveness analysis showed that bridge to transplant (BTT) with early design left ventricular assist devices (LVADs) for advanced heart failure was more expensive than medical management while appearing less beneficial. Older LVADs were pulsatile, but current second and third generation LVADs are continuous flow pumps. This study aimed to estimate comparative cost-effectiveness of BTT with durable implantable continuous flow LVADs compared to medical management in the British NHS. Methods and results: A semi-Markov multi-state economic modelwas built using NHS costs data and patient data in the British NHS Blood and Transplant Database (BTDB). Quality-adjusted life years (QALYs) and incremental costs per QALY were calculated for patients receiving LVADs compared to those receiving inotrope supported medical management. LVADs cost 80,569 ($ 127,887) at 2011 prices and delivered greater benefit than medical management. The estimated probabilistic incremental cost-effectiveness ratio (ICER) was 53,527 pound ($ 84,963)/ QALY (95% CI: 31,802- pound 94,853; pound $ 50,479-$ 150,560) (over a lifetime horizon). Estimateswere sensitive to choice of comparator population, relative likelihood of receiving a heart transplant, time to transplant, and LVAD costs. Reducing the device cost by 15% decreased the ICER to 50,106 pound ($ 79,533)/QALY. Conclusions: Durable implantable continuous flow LVADs deliver greater benefits at higher costs than medical management in Britain. At the current UK threshold of 20,000 pound to 30,000 pound/QALY LVADs are not cost effective but the ICER now begins to approach that of an intervention for end of life care recently recommended by the British NHS. Cost-effectiveness estimates are hampered by the lack of randomized trials. (C) 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.

【 授权许可】

Free